PMID- 33813266
OWN - NLM
STAT- MEDLINE
DCOM- 20211110
LR  - 20211110
IS  - 1878-3252 (Electronic)
IS  - 0946-672X (Linking)
VI  - 66
DP  - 2021 Jul
TI  - Effects of chromium supplementation on lipid profile in patients with type 2 
      diabetes: A systematic review and dose-response meta-analysis of randomized 
      controlled trials.
PG  - 126741
LID - S0946-672X(21)00031-6 [pii]
LID - 10.1016/j.jtemb.2021.126741 [doi]
AB  - BACKGROUND: The purpose of this study was to determine the influence of chromium 
      supplementation on lipid profile in patients with type 2 diabetes mellitus 
      (T2DM). METHODS: A systematic search was performed in Scopus, Embase, Web of 
      Science, the Cochrane library and PubMed databases to find randomized controlled 
      trials (RCTs) related to the effect of chromium supplementation on lipid profile 
      in patients with T2DM, up to June 2020. Meta-analyses were performed using the 
      random-effects model, and I(2) index was used to evaluate heterogeneity. RESULTS: 
      The primary search yielded 725 publications. 24 RCTs (with 28 effect size) were 
      eligible. Our meta-analysis indicated that chromium supplementation resulted in a 
      significant decrease in serum levels of triglyceride (TG) (MD: -6.54 mg/dl, 95 % 
      CI: -13.08 to -0.00, P = 0.050) and total cholesterol (TC) (WMD: -7.77 mg/dl, 95 
      % CI: -11.35 to -4.18, P < 0.001). Furthermore, chromium significantly increases 
      high-density lipoprotein (HDL) (WMD: 2.23 mg/dl, 95 % CI: 0.07-4.40, P = 0.043) 
      level. However, chromium supplementation did not have significant effects on 
      low-density lipoprotein (LDL) (WMD: -8.54 mg/dl, 95 % CI: -19.58 to 2.49, P = 
      0.129) level. CONCLUSION: Chromium supplementation may significantly improve 
      lipid profile in patients with T2DM by decreasing TG and TC and increasing HDL. 
      However, based on our analysis, chromium failed to affect LDL. It should be noted 
      that the lipid-lowering properties of chromium supplementation were small and may 
      not reach clinical importance.
CI  - Copyright (c) 2021 Elsevier GmbH. All rights reserved.
FAU - Asbaghi, Omid
AU  - Asbaghi O
AD  - Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, 
      Iran.
FAU - Naeini, Fatemeh
AU  - Naeini F
AD  - Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Science, Tehran, Iran.
FAU - Ashtary-Larky, Damoon
AU  - Ashtary-Larky D
AD  - Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of 
      Medical Sciences, Ahvaz, Iran.
FAU - Moradi, Sajjad
AU  - Moradi S
AD  - Department of Community Nutrition, School of Nutrition and Food Science, Isfahan 
      University of Medical Sciences, Isfahan, Iran; Halal Research Centre of IRI, FDA, 
      Tehran, Iran.
FAU - Zakeri, Nazanin
AU  - Zakeri N
AD  - Nutrition Research Center, Department of Clinical Nutrition, Faculty of Nutrition 
      and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Eslampour, Elham
AU  - Eslampour E
AD  - Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, 
      Iran.
FAU - Kelishadi, Mahnaz Rezaei
AU  - Kelishadi MR
AD  - Department of Community Nutrition, School of Nutrition and Food Science, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Naeini, Amirmansour Alavi
AU  - Naeini AA
AD  - Department of Community Nutrition, School of Nutrition and Food Science, Isfahan 
      University of Medical Sciences, Isfahan, Iran. Electronic address: 
      am.alavi@nutr.mui.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210323
PL  - Germany
TA  - J Trace Elem Med Biol
JT  - Journal of trace elements in medicine and biology : organ of the Society for 
      Minerals and Trace Elements (GMS)
JID - 9508274
RN  - 0 (Lipids)
RN  - 0R0008Q3JB (Chromium)
SB  - IM
MH  - Chromium/*administration & dosage/pharmacology
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy
MH  - Dietary Supplements
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Lipids/*blood
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Chromium
OT  - Diabetes
OT  - Lipid profile
OT  - Meta-analysis
OT  - RCT
OT  - Randomized controlled trial
EDAT- 2021/04/05 06:00
MHDA- 2021/11/11 06:00
CRDT- 2021/04/04 20:53
PHST- 2021/01/05 00:00 [received]
PHST- 2021/02/27 00:00 [revised]
PHST- 2021/03/04 00:00 [accepted]
PHST- 2021/04/05 06:00 [pubmed]
PHST- 2021/11/11 06:00 [medline]
PHST- 2021/04/04 20:53 [entrez]
AID - S0946-672X(21)00031-6 [pii]
AID - 10.1016/j.jtemb.2021.126741 [doi]
PST - ppublish
SO  - J Trace Elem Med Biol. 2021 Jul;66:126741. doi: 10.1016/j.jtemb.2021.126741. Epub 
      2021 Mar 23.